HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
TJP2
tight junction protein 2
Chromosome 9 Β· 9q21.11
NCBI Gene: 9414Ensembl: ENSG00000119139.21HGNC: HGNC:11828UniProt: A0A3B3IU51
209PubMed Papers
22Diseases
0Drugs
85Pathogenic Variants
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
bicellular tight junctionnucleusprotein domain specific bindingprotein-macromolecule adaptor activitycholestasis, progressive familial intrahepatic, 4hypercholanemia, familial 1autosomal dominant nonsyndromic hearing lossdeafness
✦AI Summary

TJP2 (tight junction protein 2) is a scaffold protein essential for establishing and maintaining hepatic tight junctions and bile canalicular structure. TJP2 localizes to cell-cell junctions where it regulates membrane permeability and coordinates the distribution of apical transporters, including the bile salt export pump (BSEP) 1. The protein functions through multivalent interactions within its PDZ-SH3-GuK domain to organize junction assembly via phase separation, enabling proper clustering and localization of adhesion receptors and transporters 2. Loss-of-function mutations in TJP2 cause progressive familial intrahepatic cholestasis (PFIC), characterized by impaired bile acid transport, hepatocellular injury, and progressive cirrhosis 3. In TJP2-deficient hepatocytes, loss of normal canalicular architecture, reduced claudin-1 protein levels, and mislocalization of key bile transporters result in compromised directional bile acid transport and cholestasis 41. Disease severity correlates with mutation type: patients with protein-truncating mutations on both alleles experience early infantile cholestasis with rapid progression to liver failure or death without transplantation 5. Maralixibat, an ileal bile acid transporter inhibitor, provides symptomatic improvement in PFIC patients including those with TJP2 deficiency, reducing pruritus and bile acid levels 6.

Sources cited
1
TJP2 is identified as a major PFIC gene encoding TJP2 protein
PMID: 30266155
2
TJP2 mutations cause progressive familial intrahepatic cholestasis syndromes
PMID: 35868680
3
Maralixibat improves pruritus and serum bile acids in PFIC patients including those with TJP2 deficiency
PMID: 38723644
4
ZO proteins self-organize via phase separation through PDZ-SH3-GuK multivalent interactions to organize tight junctions
PMID: 31675499
5
TJP2 defects cause PFIC with progressive cholestatic liver disease in early childhood
PMID: 30367658
6
TJP2 deficiency results in lower claudin-1, dilated canaliculi, altered transporter distribution, and mild progressive cholestasis
PMID: 33465371
7
TJP2 mutations cause disrupted apical membrane structures, distorted canalicular networks, and compromised directional bile acid transport in hepatocytes
PMID: 35284810
8
Protein-truncating TJP2 mutations (TJP2-C genotype) cause early infantile cholestasis with poor prognosis and rapid progression to liver failure
PMID: 38447037
Disease Associationsβ“˜22
cholestasis, progressive familial intrahepatic, 4Open Targets
0.80Strong
hypercholanemia, familial 1Open Targets
0.67Moderate
autosomal dominant nonsyndromic hearing lossOpen Targets
0.58Moderate
deafnessOpen Targets
0.47Moderate
hypercholanemia, familialOpen Targets
0.46Moderate
refractive errorOpen Targets
0.46Moderate
genetic disorderOpen Targets
0.42Moderate
myopiaOpen Targets
0.40Moderate
Abnormality of refractionOpen Targets
0.39Weak
migraine disorderOpen Targets
0.36Weak
autosomal recessive nonsyndromic hearing loss 4Open Targets
0.36Weak
hearing loss, autosomal recessiveOpen Targets
0.36Weak
Alzheimer diseaseOpen Targets
0.32Weak
lysosomal storage diseaseOpen Targets
0.32Weak
multiple sclerosisOpen Targets
0.32Weak
neurodegenerative diseaseOpen Targets
0.32Weak
Parkinson diseaseOpen Targets
0.32Weak
atrioventricular blockOpen Targets
0.31Weak
biliary liver cirrhosisOpen Targets
0.27Weak
primary biliary cirrhosisOpen Targets
0.27Weak
Cholestasis, progressive familial intrahepatic, 4UniProt
Hypercholanemia, familial, 1UniProt
Pathogenic Variants85
NM_004817.4(TJP2):c.1894C>T (p.Arg632Ter)Pathogenic
Cholestasis, progressive familial intrahepatic, 4|Hypercholanemia, familial 1|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 632
NM_004817.4(TJP2):c.1234C>T (p.Arg412Ter)Pathogenic
Cholestasis, progressive familial intrahepatic, 4|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 412
NM_004817.4(TJP2):c.2173C>T (p.Arg725Ter)Pathogenic
Cholestasis, progressive familial intrahepatic, 4
β˜…β˜…β˜†β˜†2025β†’ Residue 725
NM_004817.4(TJP2):c.143T>C (p.Val48Ala)Pathogenic
Hypercholanemia, familial 1|Cholestasis, progressive familial intrahepatic, 4|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 48
NM_004817.4(TJP2):c.782del (p.Tyr261fs)Pathogenic
not provided|Cholestasis, progressive familial intrahepatic, 4|TJP2-related disorder
β˜…β˜…β˜†β˜†2024β†’ Residue 261
NM_004817.4(TJP2):c.1210G>A (p.Asp404Asn)Likely pathogenic
Cholestasis, progressive familial intrahepatic, 4|TJP2-related disorder
β˜…β˜…β˜†β˜†2023β†’ Residue 404
NM_004817.4(TJP2):c.3325G>T (p.Glu1109Ter)Pathogenic
not provided|Cholestasis, progressive familial intrahepatic, 4
β˜…β˜…β˜†β˜†2023β†’ Residue 1109
NM_004817.4(TJP2):c.619C>T (p.Gln207Ter)Pathogenic
not provided|Cholestasis, progressive familial intrahepatic, 4
β˜…β˜…β˜†β˜†2022β†’ Residue 207
NM_004817.4(TJP2):c.2209G>A (p.Gly737Ser)Pathogenic
Cholestasis, progressive familial intrahepatic, 4|Melnick-Fraser syndrome
β˜…β˜…β˜†β˜†2021β†’ Residue 737
NM_004817.4(TJP2):c.2524C>T (p.Gln842Ter)Pathogenic
Cholestasis, progressive familial intrahepatic, 4|not provided
β˜…β˜…β˜†β˜†2021β†’ Residue 842
NM_004817.4(TJP2):c.239+1G>APathogenic
Cholestasis, progressive familial intrahepatic, 4
β˜…β˜…β˜†β˜†2019
NM_004817.4(TJP2):c.2327del (p.Arg775_Leu776insTer)Pathogenic
Cholestasis, progressive familial intrahepatic, 4
β˜…β˜…β˜†β˜†2019β†’ Residue 775
NM_004817.4(TJP2):c.1771C>T (p.Arg591Ter)Pathogenic
not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2018β†’ Residue 591
NM_004817.4(TJP2):c.2632C>T (p.Gln878Ter)Likely pathogenic
not provided|Cholestasis, progressive familial intrahepatic, 4
β˜…β˜…β˜†β˜†2017β†’ Residue 878
NM_004817.4(TJP2):c.469G>T (p.Glu157Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 157
NM_004817.4(TJP2):c.590del (p.Arg197fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 197
NM_004817.4(TJP2):c.1845dup (p.Glu616Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 616
NM_004817.4(TJP2):c.637C>T (p.Arg213Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 213
NM_004817.4(TJP2):c.2461_2462del (p.Val821fs)Likely pathogenic
Cholestasis, progressive familial intrahepatic, 4
β˜…β˜†β˜†β˜†2025β†’ Residue 821
NM_004817.4(TJP2):c.2880+1G>ALikely pathogenic
not provided
β˜…β˜†β˜†β˜†2025
View on ClinVar β†—
Related Genes
MPDZProtein interaction100%ARHGEF2Protein interaction100%CTNNB1Protein interaction100%MARVELD2Protein interaction99%RAPGEF2Protein interaction98%WWTR1Protein interaction97%
Tissue Expression6 tissues
Liver
100%
Brain
90%
Lung
77%
Ovary
69%
Bone Marrow
6%
Heart
3%
Gene Interaction Network
Click a node to explore
TJP2MPDZARHGEF2CTNNB1MARVELD2RAPGEF2WWTR1
PROTEIN STRUCTURE
Preparing viewer…
PDB3E17 Β· 1.75 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.82LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.69 [0.57–0.82]
RankingsWhere TJP2 stands among ~20K protein-coding genes
  • #2,005of 20,598
    Most Researched209 Β· top 10%
  • #878of 5,498
    Most Pathogenic Variants85 Β· top quartile
  • #7,008of 17,882
    Most Constrained (LOEUF)0.82
Genes detectedTJP2
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
Progressive Familial Intrahepatic Cholestasis.
PMID: 30266155
Clin Liver Dis Β· 2018
1.00
2
Overview of Progressive Familial Intrahepatic Cholestasis.
PMID: 35868680
Clin Liver Dis Β· 2022
0.90
3
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
PMID: 38723644
Lancet Gastroenterol Hepatol Β· 2024
0.80
4
Phase Separation of Zonula Occludens Proteins Drives Formation of Tight Junctions.
PMID: 31675499
Cell Β· 2019
0.70
5
Alterations of the gut commensal
PMID: 40360188
Virulence Β· 2025
0.64